Browsing by Author "Jensen, Søren Beck"

Now showing items 1-3 of 3

    • Complement factors B, D, C3bBbP and risk of future venous thromboembolism 

      Skjeflo, Espen Waage; Evensen, Line Holtet; Jensen, Søren Beck; Latysheva, Nadezhda; Michelsen, Annika Elisabet; Ueland, Thor; Brækkan, Sigrid Kufaas; Hindberg, Kristian Dalsbø; Snir, Omri; Mollnes, Tom Eirik; Hansen, John Bjarne (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-03-07)
      The complement system appears to be involved in the pathogenesis of venous thromboembolism (VTE).<p> <p>We investigated the association of complement factors (CF) B, D, and the alternative pathway convertase, C3bBbP, measured at inclusion, with the risk of future VTE in a nested case-control study; 380 VTE patients and 804 age- and sex-matched controls derived from the Tromsø study. Odds ratios ...

    • High plasma levels of C1-inhibitor are associated with lower risk of future venous thromboembolism 

      Grover, Steven P.; Snir, Omri; Hindberg, Kristian Dalsbø; Englebert, Tatianna M.; Brækkan, Sigrid Kufaas; Morelli, Vania Maris; Jensen, Søren Beck; Wolberg, Alisa S.; Mollnes, Tom Eirik; Ueland, Thor; Mackman, Nigel; Hansen, John Bjarne (Journal article; Tidsskriftartikkel; Peer reviewed, 2023-03-31)
      Background - C1-inhibitor (C1INH) is a broad-acting serine protease inhibitor with anticoagulant activity. The impact of C1INH plasma levels within the normal physiological range on risk of venous thromboembolism (VTE) is unknown. We assessed the association of plasma C1INH levels and VTE risk and evaluated the impact of C1INH on thrombin and plasmin generation in ex vivo assays.<p> <p>Methods - ...

    • Plasma lipopolysaccharide-binding protein is a biomarker for future venous thromboembolism: Results from discovery and validation studies 

      Jensen, Søren Beck; Latysheva, Nadezhda; Hindberg, Kristian; Ueland, Thor (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-04-14)
      Background<p> <p>Effect-size underestimation impedes biomarker identification. Long follow-up time in prospective studies attenuates effect-size estimates for transient biomarkers, while disease category–specific biomarkers are affected by merging of categories. Venous thromboembolism (VTE) encompasses deep vein thrombosis (DVT) and pulmonary embolism (PE). <p>Objectives <p>(i) To re-analyze untargeted ...